- Home
- GHI vs CHRS Comparison
GHI vs CHRS Comparison
Compare GHI & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
GHI
Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Current Price
Company Overview
Basic Information| Metric | GHI | CHRS |
|---|---|---|
| Founded | 1998 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.5M | 186.0M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | GHI | CHRS |
|---|---|---|
| Price | $7.13 | $1.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $13.00 | $4.02 |
| AVG Volume (30 Days) | 202.0K | ★ 895.2K |
| Earning Date | 02-19-2026 | 11-06-2025 |
| Dividend Yield | ★ 21.48% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.17 | ★ 1.34 |
| Revenue | $26,247,399.00 | ★ $277,728,000.00 |
| Revenue This Year | $201.02 | N/A |
| Revenue Next Year | $2.87 | $67.31 |
| P/E Ratio | $40.84 | ★ $1.07 |
| Revenue Growth | N/A | ★ 152.07 |
| 52 Week Low | $6.01 | $0.71 |
| 52 Week High | $13.29 | $1.89 |
Technical Indicators
Market Signals| Indicator | GHI | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 53.00 | 52.34 |
| Support Level | $6.52 | $1.27 |
| Resistance Level | $7.35 | $1.49 |
| Average True Range (ATR) | 0.37 | 0.08 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 69.74 | 47.73 |
Price Performance
Historical ComparisonAbout GHI Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.